Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Eli Lilly's experimental oral pill, orforglipron, has shown promising results in Phase 3 trials, effectively lowering weight and blood sugar levels similar to Ozempic in diabetes patients. This once-daily pill offers a convenient,

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.